Home › Amarantus Requests Rare Pediatric Disease Designation From FDA
 

Keywords :   


Amarantus Requests Rare Pediatric Disease Designation From FDA

2016-02-09 01:17:54| drugdiscoveryonline News Articles

Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF.

Tags: disease requests rare designation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.05Whistleblower: Boeing supplier sent faulty parts
09.05Will AI dream up the hit TV shows of the future?
09.05Interest rates expected to stay at 16-year high
09.05Emma Roberts Is Kiko Milanos First Global Brand Ambassador
08.05New regulations and rules for public land management
08.05IBBA seeks Executive Vice President
08.05The 75th Brangus Celebration: Honoring heritage and innovation
08.05Cull cow prices in 2024
More »